Table 2.
Univariable and multivariable analysis: the likelihood (displayed as odds ratio [95% confidence interval]) of receiving guideline‐recommended therapy for diabetics compared with non‐diabetics
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||
| Beta‐blocker | 1.060 [0.932–1.205] | 1.065 [0.998–1.138] | 1.082 [0.950–1.231] | 1.042 [0.914–1.188] |
| RAS inhibitor | 0.804 [0.708–0.912] | 0.803 [0.752–0.857] | 0.848 [0.744–0.966] | 0.853 [0.747–0.975] |
| MRA | 1.007 [0.910–1.114] | 1.011 [0.960–1.065] | 0.965 [0.871–1.070] | 0.952 [0.857–1.058] |
| Diuretics | 1.564 [1.355–1.806] | 1.526 [1.417–1.643] | 1.393 [1.202–1.616] | 1.284 [1.103–1.495] |
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OSAS, obstructive sleep apnoea syndrome; RAS, renin–angiotensin system.
Model 1 included age and gender. Model 2 included age, gender, NYHA classification, and LVEF. Model 3 included age, gender, NYHA classification, LVEF, hypertension, COPD, OSAS, thyroid disease, renal insufficiency (defined as eGFR < 60 mL/min or a history of renal insufficiency), and atrial fibrillation.